Edition:
United Kingdom

Arcturus Therapeutics Ltd (ARCT.OQ)

ARCT.OQ on NASDAQ Stock Exchange Global Market

5.17USD
20 Apr 2018
Change (% chg)

$-0.48 (-8.50%)
Prev Close
$5.65
Open
$5.59
Day's High
$5.64
Day's Low
$5.16
Volume
5,327
Avg. Vol
12,943
52-wk High
$15.19
52-wk Low
$4.84

Summary

Name Age Since Current Position

Stuart Collinson

55 2014 Executive Chairman of the Board

Mark Herbert

2018 Interim President

Christine Esau

2018 Vice President of Research and Development

Daniel Geffken

60 2017 Director

David Shapiro

62 2017 Director

Orli Tori

53 2017 Director

Craig Willett

2013 Director

Biographies

Name Description

Stuart Collinson

Dr. Stuart J.M. Collinson Ph.D., is Executive Chairman of the Board of the company since May 2014 and has served as Executive Chairman since January 2015. He is a partner at Forward Ventures and also the Executive Chairman of Tioga Pharmaceuticals, Inc. Previously he was Chairman, Chief Executive Officer and President of Aurora Biosciences Corp. (acquired by Vertex Pharmaceuticals Inc.). Before Aurora, Dr. Collinson was Chief Executive Officer of Andaris Limited (acquired by Quadrant, now part of Perrigo). He held senior management positions at GlaxoWellcome plc (now GlaxoSmithKline plc) and Baxter International Inc., and was a consultant with The Boston Consulting Group. Dr. Collinson was previously a director of Affinium Pharmaceuticals, Inc. (acquired by Debiopharma Group), Cabrellis Pharmaceuticals Corp. (acquired by Pharmion Corp., now part of Celgene Corp.), Conforma Therapeutics Corp. (acquired by BiogenIdec, Inc.), GeneOhm Sciences, Inc. (acquired by Becton, Dickinson and Company), NovaCardia, Inc. (acquired by Merck & Co, Inc.), and Proprius Pharmaceuticals, Inc. (acquired by Cypress Bioscience, Inc.), and Vertex Pharmaceuticals Inc. Dr. Collinson received an M.B.A. from Harvard Business School and a Ph.D. in Physical Chemistry from the University of Oxford.

Mark Herbert

Mr. Mark R. Herbert is Interim President of the Company. Mr. Herbert joined Arcturus in 2015, and previously served as Vice President of Business Development and Alliance Management. He previously was Head of U.S. Business Development and Sales at STA Pharmaceutical Co., Ltd., WuXi AppTec's small molecule development and manufacturing division, where he was responsible for all North American business development and marketing activities. Prior to WuXi AppTec, Mr. Herbert served as Director of Pharmaceutical Sciences at Aragon Pharmaceuticals, Inc. which was acquired by Johnson & Johnson in 2013. Mr. Herbert's background includes over 15 years of experience in business and technical development of large and small molecules working across a number of different platforms and therapeutic areas. He is an author or inventor on over 35 peer-reviewed manuscripts and patents and has led or contributed to the submission of 13 investigational new drug (IND) applications and one new drug application (NDA).

Christine Esau

Ms. Christine Esau is Vice President of Research and Development of the company. She joined Arcturus in 2015, and most recently served as Senior Director of Translational Research. Dr. Esau was previously lead biologist at Ionis Pharmaceuticals and Regulus Therapeutics and served as Chief Scientific Officer of AptamiR Therapeutics. She has performed pioneering work in microRNA biology and anti-miRNA targeting technology development, resulting in landmark, highly cited papers and early patent filings. As lead biologist for the anti-miR-122 program for treatment of HCV with Regulus, she moved the program from discovery biology to lead compound selection, directing pharmacology, PK/PD, safety, and mechanism of action studies. At Regulus, she led exploratory efforts to identify novel microRNA targets for metabolic diseases, in the process establishing an extensive network of academic collaborators. Dr. Esau led the anti-miR-33 program for atherosclerosis which came out of these efforts and was the basis for Regulus' partnership with Astra-Zeneca. While Chief Scientific Officer of AptamiR Therapeutics, Dr. Esau worked to develop a microRNA based therapy for the treatment of obesity. Dr. Esau earned a B.S. degree in biology from the California Institute of Technology and a Ph.D. from the Massachusetts Institute of Technology.

Daniel Geffken

Mr. Daniel E. Geffken CPA., Director of the company since November 2017, Mr. Geffken had served on the Alcobra Board since their initial public offering in May 2013. Since October 2011, he has been Managing Director of Danforth Advisors, LLC, a management consulting firm that provides financial and strategic support to emerging life science companies. Mr. Geffken has also been Chief Financial Officer or Chief Operating Officer of eight companies, four of which were U.S. public reporting companies and six of which were life science companies. He has a B.S. in Economics from The Wharton School, University of Pennsylvania, and a M.B.A. from Harvard Business School.

David Shapiro

Dr. David M. Shapiro M.D., is Director of the company since November 2017. He currently serves as Chief Medical Officer and Executive Vice President of development at Intercept Pharmaceuticals, Inc., a public pharmaceutical company, a position he has held since 2008. He has over 25 years of clinical development experience in the pharmaceutical industry. Dr. Shapiro founded a consulting company, Integrated Quality Resources, that focused on development stage biopharmaceutical companies and was active in this role from 2005 to 2008. From 2000 to 2005, Dr. Shapiro was Executive Vice President, medical affairs and Chief Medical Officer of Idun Pharmaceuticals, Inc., prior to its acquisition by Pfizer Inc. From 1995 to 1998, he was President of the Scripps Medical Research Center at Scripps Clinic. He also served as Vice President, clinical research at Gensia Pharmaceuticals, Inc. and as Director and Group Leader, hypertension clinical research at Merck Research Laboratories from 1985 to 1990. Dr. Shapiro has authored more than 20 peer-reviewed publications and organized and chaired several conferences aimed at improving product development. Dr. Shapiro served on the board of directors of Altair Therapeutics, Inc. from 2008 to 2010 and served for two terms on the Executive Committee of the Board of the American Academy of Pharmaceutical Physicians, from 1997 to 2000 and from 2004 to 2005. He is an elected Fellow of both the Royal College of Physicians of London and the Faculty of Pharmaceutical Physicians of the United Kingdom. He received his medical degree from Dundee University & Medical School, and undertook his postgraduate medical training in the university affiliated hospitals in Oxford, United Kingdom and the University of Vermont.

Orli Tori

Ms. Orli Tori is Director of the company since November 2017, Orli Tori had served on the Alcobra Board since August 2016. Ms. Tori is an experienced executive with over 20 years of practice in leading teams towards their goals and beyond. Since 2012 and until recently, Ms. Tori served as Chief Executive Officer of BIRAD Ltd., managing Bar Ilan University's IP and commercialization efforts as well as all research collaborations with Industry. During her tenure, the company built a diverse portfolio of companies based on University IP. Before joining BIRAD, Ms. Tori spent 20 years in the pharmaceutical industry, fulfilling different positions including, General Manager of Neopharm Israel Ltd. from 2007 through 2012, ($200 Million revenues), and SVP Corporate BD of the Neopharm Group, and was responsible for the group overall corporate development activities, including structuring, negotiating and closing transactions. Ms. Tori serves as a board member at Collplant Ltd. (CLPT) and is former chairperson of the Israeli Technology Transfer Organization. Ms. Tori obtained her M.Sc. in Microbiology (cum laude) and B.Sc. in Life Sciences at Tel Aviv University in Tel Aviv, Israel, and graduated the Executive Program for senior business managers at the Tel Aviv University School of Business.

Craig Willett

Mr. Craig Willett CPA., is Director of the company since March 2013. He is the President and CEO of Voice of the Entrepreneur, Inc. providing start up coaching services to the next generation of entrepreneurs. He is the past President and CEO of UTAZ Development Corporation, the innovator of "Own For Less Than Rent" office space. Craig has demonstrated his ability to assemble capital and lead development teams to extraordinary success as reflected in the success of the nearly $700 million of projects to which he has offered his vision and leadership. He is also a real estate broker and CPA and holds bachelor's and master's degrees in accounting from Brigham Young University. As the founder of an accounting firm specializing in business and real estate tax issues he is a recognized business and tax authority testifying in both houses of Congress and has been quoted in the New York Times, the Washington Post, and the Wall Street Journal. Craig was also a founding director of Capital Community Bank. He is a Founder in the Brigham Young University Center for Entrepreneurship. He has served on many community development boards most recently Banner Children's Hospital Capital Campaign Board.

Basic Compensation